VELA Investment Management LLC Increases Stock Position in PROCEPT BioRobotics Corporation $PRCT

VELA Investment Management LLC raised its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 61.4% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 117,894 shares of the company’s stock after purchasing an additional 44,855 shares during the period. VELA Investment Management LLC owned 0.21% of PROCEPT BioRobotics worth $2,662,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of PROCEPT BioRobotics in the second quarter worth about $109,961,000. Alliancebernstein L.P. grew its holdings in PROCEPT BioRobotics by 58.6% during the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after buying an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in PROCEPT BioRobotics by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after buying an additional 1,218,815 shares in the last quarter. Mackenzie Financial Corp increased its stake in PROCEPT BioRobotics by 8.2% in the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after acquiring an additional 118,971 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its stake in PROCEPT BioRobotics by 11.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company’s stock worth $47,841,000 after acquiring an additional 155,601 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on PRCT. Robert W. Baird set a $20.00 target price on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Piper Sandler reduced their price target on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. Evercore set a $23.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Wells Fargo & Company lowered shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective for the company. in a research report on Wednesday, August 5th. Finally, Citigroup cut shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $25.09.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Insider Activity

In other news, CEO Larry Wood purchased 23,900 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the acquisition, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock opened at $22.76 on Monday. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -11.73 and a beta of 0.91. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The stock has a 50 day moving average price of $20.35 and a 200-day moving average price of $23.66. PROCEPT BioRobotics Corporation has a one year low of $16.67 and a one year high of $41.51.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.35) EPS. Equities analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.